Trevena, Inc. (NASDAQ:TRVN – Get Free Report) shares crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $0.01 and traded as low as $0.0004. Trevena shares last traded at $0.0004, with a volume of 117 shares trading hands.
Trevena Price Performance
The stock has a market capitalization of $383.60, a PE ratio of -0.00 and a beta of -0.55. The stock’s fifty day moving average is $0.01 and its 200-day moving average is $0.01.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on developing medicines for the treatment of acute and chronic pain, as well as disorders of the central nervous system. The company’s research has centered on G protein–coupled receptors and its “biased ligand” drug-discovery platform, which is intended to produce therapeutic effects while potentially reducing certain side effects associated with conventional treatments. Trevena’s principal commercial product is OLINVYK (oliceridine) injection, an opioid analgesic approved by the U.S. Food and Drug Administration in 2020 for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.
Featured Articles
- Five stocks we like better than Trevena
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
